Hutchison China MediTech (Chi-Med) has announced, effective from February 1, Paul Rutherford Carter has been appointed as senior independent non-executive director and member of the audit committee, Remuneration Committee and Technical Committee of Chi-Med; and Shigeru Endo tendered his resignation as non-executive director and Christopher Nash tendered his resignation as senior independent non-executive director and member of audit committee and remuneration committee effective on the same date.
Carter has more than 25 years of experience in the pharmaceutical industry. From 2006 to 2016, Carter served in various senior executive roles at Gilead Sciences, a research-based biopharmaceutical company, with the last position as executive vice president, Commercial Operations. In this role, Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of Gilead’s products. Prior to joining Gilead, he spent 14 years with GlaxoSmithKline (GSK) and its group companies, with the last position as a Regional head of the International business in Asia.
Carter is currently a director of Alder Biopharmaceuticals. He was previously a director of Gilead Sciences, Gilead Sciences International and Gilead Sciences Europe within the past five years.
Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the Chartered Institute of Management Accountants in the U.K.
Simon To, chairman of Chi-Med, said, “We thank Shigeru Endo and Christopher Nash for their invaluable contributions to the Company during their tenure and welcome Carter to the Board whose experience in the global biopharmaceutical industry will be important to the Company.”
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.